News from Helsinn Group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Oct 10, 2016, 02:00 ET Helsinn Group Introduces Helsinn Investment Fund

~ Helsinn Group creates new investment fund in 40th anniversary year ~ ~ The new fund will focus on supporting early-stage investment...


Jun 13, 2016, 03:00 ET Helsinn Group Hosts a Satellite Symposium on Shared Decision Making in Supportive Care, at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) Annual Meeting 2016 on June 24th

A Panel of World-renowned Experts Will Share Practical Recommendations on Best Practice in Supporting People With Cancer, Offering Advice on...


Jun 02, 2016, 06:00 ET Helsinn Group Signs Exclusive Agreement With Grünenthal Group for the Registration, Marketing, Promotion and Sales of Akynzeo® (Netupitant/Palonosetron Combo) in Chile

Helsinn, the Swiss Group focused on building quality cancer care products, and Grünenthal Group have announced today that they have signed an...


Apr 26, 2016, 08:00 ET Helsinn Healthcare SA, The University of Texas MD Anderson Cancer Center Enter Strategic Alliance to Improve Life of Patients Conducting Clinical Studies in Cancer Supportive and Palliative Care

- Collaboration Plans a Comprehensive Range of Clinical Studies to Evaluate Helsinn Commercialized and/or Under Development Pipeline Products in...


Apr 25, 2016, 06:00 ET Helsinn Group Signs Exclusive Agreement With Purdue Pharma Canada for the Distribution and Licensing Rights of Akynzeo® (Netupitant/Palonosetron Combo) in Canada

Helsinn, the Swiss Group focused on building quality cancer care products and Purdue Pharma Canada today announce that they have signed an...


Jan 12, 2016, 05:30 ET Helsinn célèbre son 40e anniversaire

  ~ Depuis 40 ans, nous aidons les patients à améliorer leur qualité de vie ~  Helsinn, le Groupe pharmaceutique...


Jan 11, 2016, 10:00 ET Helsinn Celebrates its 40th Anniversary

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, is delighted to launch its 40th anniversary celebrations in San...


Nov 13, 2015, 08:00 ET Helsinn Group and Eisai Inc. Announce Inclusion of AKYNZEO® (netupitant/palonosetron) in American Society of Clinical Oncology (ASCO) Antiemetics Guideline Update

Helsinn Group and Eisai Inc. announced today that the American Society of Clinical Oncology (ASCO) has published a focused update to its clinical...


Oct 14, 2015, 10:19 ET Helsinn's AKYNZEO® (netupitant/palonosetron) Nominated Within the Category "Best Pharmaceutical Agent of the Year" at The Galien Foundation Prix Awards, New York

Helsinn Group announces that AKYNZEO® (netupitant/palonosetron) has been nominated by the Galien Foundation within the category "Best...


Sep 09, 2015, 02:00 ET Additional Data for anamorelin in ROMANA 1 and ROMANA 2 Studies Presented at 2015 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC), in Denver

Helsinn, a Swiss Group focused on building quality cancer care, announced today that additional study results from the ROMANA Phase III program...


Sep 08, 2015, 06:22 ET Helsinn Group Signs Exclusive Agreement With BIAL for Distribution and Licence of Anamorelin in Spain, Portugal, Angola and Mozambique

Anamorelin is a novel ghrelin receptor agonist in development for the treatment of cancer anorexia-cachexia syndrome  Helsinn, the Swiss...


Sep 03, 2015, 02:00 ET Helsinn Group Signs Exclusive Agreement With Mundipharma for the Distribution and Licence of anamorelin in Switzerland and Liechtenstein

This exclusive agreement builds on broad partnerships with Mundipharma in cancer supportive care across multiple global...


Feb 09, 2015, 02:06 ET Helsinn Group Signs Exclusive Agreement With Mundipharma for Distribution and Licensing of Netupitant/Palonosetron (NEPA) in Brazil

The exclusive agreement builds on our existing partnerships in the area of cancer supportive care across multiple global territories...


Jan 12, 2015, 09:00 ET Helsinn to Present at the 33rd Annual J.P. Morgan Healthcare Conference (January 12-15, 2015)

Helsinn, the Swiss Group focused on building quality cancer care, is pleased to announce that Riccardo Braglia, Helsinn's Chief Executive Officer,...


Jan 12, 2015, 01:00 ET Helsinn Reaches Settlement Agreement Regarding Patent Dispute on ALOXI®

Helsinn Healthcare SA announces that it has entered into a settlement agreement with Sandoz Inc. to resolve their patent litigations relating to...


Sep 27, 2014, 03:00 ET Pivotal Phase III Trial Data for Anamorelin in ROMANA 1 and 2 Studies in Non-Small Cell Lung Cancer Patients with Anorexia-Cachexia Shows Significant Increase in Lean Body Mass, Body Weight and Improved Symptoms

The Helsinn Group, a Company focused on building quality cancer care, announces that anamorelin, its novel, once-daily ghrelin receptor agonist...


Jul 17, 2014, 02:00 ET Helsinn Group and Chugai Pharma Marketing Enter Into Agreement for Marketing Rights of Netupitant-Palonosetron Fixed-Dose Combination (NEPA) in the UK and Ireland and for Palonosetron Monotherapy in the UK

Under the exclusive agreement, Chugai Pharma Marketing gains rights for the marketing of palonosetron in the UK and NEPA in the UK and in Ireland...


Jul 10, 2014, 06:25 ET Helsinn Announces That Phase 2/3 Pivotal Trials for NEPA (netupitant 300 mg + oral palonosetron 0.50 mg), Will be Published in the Annals of Oncology

Helsinn Group, the company focused on building quality cancer care, today announces that the complete results of the three Phase 2/3 pivotal...


Jun 30, 2014, 07:43 ET Helsinn Group and Gen Ilaç Establish a Collaboration for Anamorelin in Turkey

Exclusive distribution and licensing agreement signed for the commercialization of Helsinn's compound currently in development for the treatment...


Dec 03, 2013, 09:59 ET Inauguración oficial de la Oficina de Representación en China de Helsinn Group

Helsinn Group, la compañía farmacéutica suiza de propiedad privada e independiente, que cuenta con presencia mundial construida...


Dec 03, 2013, 09:46 ET Helsinn Group inaugure officiellement son bureau de représentation en Chine

Helsinn Group, société pharmaceutique suisse privée et indépendante présente à l'international depuis 35 ans,...


Dec 03, 2013, 05:00 ET Helsinn Group's Representative Office in China: Official Inauguration

 Helsinn Group, the independent, privately-owned, Swiss pharmaceutical company, with a worldwide presence built over 35 years, lands in...


Dec 07, 2011, 12:15 ET Helsinn comienza un estudio de ampliación del programa clínico de anamorelin en fase tardía

Helsinn comienza un estudio de ampliación del programa clínico de anamorelin en fase tardía para el cáncer de pulmón de...


Dec 07, 2011, 07:00 ET Helsinn Initiates Extension Study in Late-Stage Anamorelin Clinical Program for Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia

 Helsinn, a Swiss-based pharmaceutical company, announced today that its US subsidiary, Helsinn Therapeutics Inc., has enrolled the first...